Assessment of protective efficacy of live and killed vaccines based on a non-encapsulated mutant of Streptococcus suis serotype 2.
The protective efficacy of a live and killed non-encapsulated isogenic mutant of Streptococcus suis serotype 2 was determined in pigs, and compared with the efficacy of the capsulated wild-type strain. SPF pigs were vaccinated twice intramuscularly at 4 and 7 weeks of age with a dose of 1 x 10(9) formalin-killed CFU of the wild-type (WT-BAC), formalin-killed non-encapsulated mutant (CM-BAC) or live non-encapsulated mutant (CM-LIVE) strain. After 2 weeks, vaccinated pigs and non-vaccinated controls were challenged intravenously with 1 x 10(7) CFU of the homologous, wild-type S. suis serotype 2 strain. Protection was evaluated by clinical, bacteriological, serological and post-mortem examinations. All pigs vaccinated with WT-BAC were completely protected against challenge with the homologous serotype. Pigs vaccinated with CM-BAC were partially protected. Although all pigs vaccinated with CM-BAC survived the challenge, four out of five pigs developed clinical signs of disease for several days. Compared to the WT-BAC and CM-BAC, the CM-LIVE vaccine was less protective. Two out of five pigs vaccinated with CM-LIVE died in the course of the experiment and all of them developed specific clinical signs of disease for several days. The protective efficacy of the vaccines could be associated with serum antibody titers. Antibody titers against cells of wild-type and non-encapsulated mutant strains as well as against muramidase-released proteins (MRP) were high in pigs vaccinated with WT-BAC and CM-BAC. Pigs vaccinated with CM-LIVE showed lower antibody titers. Antibody titers against purified capsular polysaccharides (CPS) of S. suis serotype 2 were only found in pigs vaccinated with WT-BAC. These findings indicate that CPS and other bacterial components of WT-BAC are probably essential for full protection against homologous challenge.
Wisselink
Henk J
HJ
Division of Infectious Diseases and Food Chain Quality, Institute for Animal Science and Health, ID-Lelystad, P.O. Box 65, 8200 AB Lelystad, The Netherlands. h.j.wesselink@id.wag-ur.nl
Stockhofe-Zurwieden
Norbert
N
Hilgers
Luuk A T
LA
Smith
Hilde E
HE
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood*; D015169:Colony Count, Microbial; D007273:Injections, Intramuscular / Q000662:veterinary; D009154:Mutation; D013047:Specific Pathogen-Free Organisms; D013290:Streptococcal Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D022541:Streptococcal Vaccines / Q000008:administration & dosage / Q000276:immunology; D017011:Streptococcus suis / Q000235:genetics / Q000276:immunology*; D013552:Swine; D013553:Swine Diseases / Q000276:immunology / Q000517:prevention & control*; D016896:Treatment Outcome; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated
D000907:Antibodies, Bacterial; D022541:Streptococcal Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated